{
    "root": "909bac1c-3936-4bf5-bcda-eebc8a0e24ee",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Famotidine",
    "value": "20250509",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8"
        }
    ],
    "indications": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : • active duodenal ulcer ( du ) . • active gastric ulcer ( gu ) . • symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . • erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : • treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . • reduction risk duodenal ulcer recurrence .",
    "contraindications": "indication recommended ( ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastric ulcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; 40 mg twice daily adults pathological hypersecretory conditions 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du recurrence 20 mg daily • full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( , ) ( ) : • take daily bedtime twice daily morning bedtime without food .",
    "warningsAndPrecautions": "famotidine tablets usp , 40 mg , white , round , biconvex , film-coated tablets debossed “ ” one side “ 12 ” side . supplied follows : bottles 14 ndc 68788-8733-4 bottles 30 ndc 68788-8733-3 bottles 60 ndc 68788-8733-6 bottles 90 ndc 68788-8733-9 storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense usp tight , light-resistant container .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h 2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:              • active duodenal ulcer (DU).              • active gastric ulcer (GU).              • symptomatic nonerosive gastroesophageal reflux disease (GERD).              • erosive esophagitis due to GERD, diagnosed by biopsy.          \n                  Famotidine tablets are indicated in adults for the:              • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).              • reduction of the risk of duodenal ulcer recurrence.",
    "contraindications_original": "Indication Recommended Dosage (                          ) Adult and Pediatric Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice daily Active Gastric Ulcer 40 mg once daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or 40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily • See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. (                 ,                  ) Administration ( ): • Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.",
    "warningsAndPrecautions_original": "Famotidine Tablets USP, 40 mg, are white, round, biconvex, film-coated tablets debossed with “T” on one side and “12” on the other side. They are supplied as follows:          \n                   Bottles of 14                                    NDC 68788-8733-4    \n                  Bottles of 30                                     NDC 68788-8733-3    \n                  Bottles of 60                                     NDC 68788-8733-6       \n                  Bottles of 90                                     NDC 68788-8733-9    \n                  \n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H             2) receptor antagonists."
}